Chemotherapy for high-grade gliomas

British Journal of Cancer

Volumn 82, Issue 8, 2000, Pages 1371-1380

  Galanis, E ^a   Buckner, J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anaplastic astrocytoma; Chemotherapy; Glioblastoma multiforme; High grade gliomas; Oligoastrocytoma; Oligodendroglioma

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; 6 O BENZYLGUANINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AZIRIDINYLBENZOQUINONE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; DACARBAZINE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROXYUREA; IRINOTECAN; LEFLUNOMIDE; LOBRADIMIL; LOMUSTINE; MISONIDAZOLE; MITOLACTOL; NITROSOUREA; PACLITAXEL; PROCARBAZINE; RETINOIC ACID; STREPTOZOCIN; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; THIOTEPA; UNINDEXED DRUG; VINCRISTINE;

BLOOD TOXICITY; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HUMAN; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VISUAL IMPAIRMENT;

EID: 0034024340     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1075     Document Type: Review

References (117)

1. Ameri A, Poisson M, Chen QM, et al (1993) Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neuro-Oncol 17: 43-46
2. Barba D, Saris SC, Holder C, et al (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175
3. Belanich M, Pastor M, Randall T, et al (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783-788
4. Beretta L, Gingras A-C, Svitkin YV, Hall MN and Sonenberg N (1996) Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. Embo J 15: 6578-6664
5. Berger MS, Prados MD, Van Gilder JC, et al (1997) Phase II Trial of GLI 328 HSV-TK gene therapy in recurrent glioblastoma. Cancer Gene Ther 4: 542
6. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumors cells. Science 274: 373-376
7. Bleehen NM, Roberts JT, Senanayake F, et al (1998) Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG)-BR05. Proc Am Soc Clin Oncol 17: 400a
8. Bower M, Newlands ES, Bleehen NM, et al (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488
9. Brada M and Sharpe G (1996) Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old? Eur J Cancer 32A: 2193-2194
10. Brady LW, Miyamoto C, Woo DV, et al (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22: 225
11. Brem H, Domb A, Lenartz D, et al (1992) Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid and sebacic acid. J Control Rel 19: 325-330
12. Brem H, Piantadosi S, Burger PC, et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 345: 1008-1012
13. Broder LE and Carter SK (1970) Clinical brochure BCNU (NSC-409962). Bethesda, MD
14. Brown M, Cairncross JG, Vick NA, et al (1990) Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan. Neurology 40: 397-398
15. Buckner JC, Brown LD and Cascino TL (1989) Recombinant alpha-interferon and BCNU in recurrent gliomas. J Biol Response Mod 8: 332-333
16. Buckner JC, Brown LD and Cascino TL (1990) Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neuro-Oncol 9: 249-254
17. Burger P, Vogel F, Green S and Strike T (1985) Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 56: 1106-1111
18. Burger P, Scheithauer B and Vogel F (1991) Surgical Pathology of the Nervous System and its Coverings. Churchill Livingstone: New York
19. Cairncross JG and Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360-364
20. Cairncross JG and MacDonald DR (1991) Chemotherapy for oligodendroglioma: progress report. Arch Neurol 48: 225
21. Cairncross JG, Macdonald DR and Ramsay DA (1992) Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31: 78-82
22. Cairncross G, Macdonald D, Ludwin S, et al (1994) Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013-2021
23. Cascino TL, Brown LD and Morton FM (1988) Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol 11: 586-588
24. Chamberlain MC and Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066-2071
25. Chamberlain MC, Prados MD and Silver PA (1988) A phase II trial of oral melphalan in recurrent primary brain tumors. Am J Clin Oncol 11: 52-54
26. Chang CH, Horton J, Schoenfeld D, et al (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997
27. Chang SM, Kuhn JG, Rizzo J, et al (1998) Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol 16: 2188-2194
28. Cloughesy TF, Blaack KL, Gobin UP, et al (1999) Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurg 44: 270-278
29. Cohadon F, Aouad N, Rougier A, Vital C, Rivel J and Dartigues J (1985) Histologic and nonhistologic factors correlated with survival time in supratentorial astrocytic tumors. J Neuro-Oncol 3: 105-111
30. Cokgor I, Akabani G, Friedman AH (1999) Newly diagnosed malignant glioma patients treated with 131I/anti-tenascin monoclonal antibody (MAB) 81C6 via surgically created resection cavities: Results of a phase I trial. Neuro-Oncol 1: S107
31. Coyle T, Baptista J and Winfield J (1990) Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol 8: 2014-2018
32. D'Amato RJ, Loughnan MS, Flynn E and Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-1085
33. Daums-Duport C, Scheithauer B, O'Fallon J and Kelly P (1988) Grading of astrocytomas: a simple and reproducible method. Cancer 62: 2152-2165
34. Deutsch M, Green SB, Strike TA, et al (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16: 1389
35. Dietrich PY, Saas P, Walker PR, et al (1997) Immunobiology of gliomas: new perspectives for therapy. Ann NY Acad Sci 824: 124-440
36. Dinapoli RP, Brown LD, Arusell RM, et al (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high grade glioma. J Clin Oncol 11: 1316
37. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3: 837-847
38. Domb A, Bogdansky S, Olivi A, et al (1991) Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants. Polymer Preprints 32: 219-220
39. Elliott TE, Buckner JC and Cascino TL (1991) Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neuro-Oncol 10: 27-30
40. Elliott TE, Dinapoli RP, O'Fallon JR, et al (1997) Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high-grade astrocytoma. J Neuro-Oncol 33: 239-250
41. EORTC Brain Tumor Cooperative Group (1985) Effect of AZQ(1,4 Cyclohexadiene-1,4-diacarbamic-acid-2,5-bis 1-aziridynyl-d3, 6 dioxodiethylester) in recurring supratentorial malignant brain gliomas: a phase II study. Eur J Clin Oncol 21: 143-146
42. Eyre HJ, Quagliana JM, Eltringham JR, et al (1983) Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. J Neuro-Oncol 1: 171-177
43. Fine HA and Antman KH (1992) High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant 10: 315-321
44. Fine HA, Dear KBG, Loeffler JS, et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597
45. Fine HA, Figg WD, Jaeckle K, et al (2000) Phase II trials of the antiangiogenic agent thalidomide in patient with recurrent high-grade gliomas. J Clin Oncol 18: 708-715
46. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science 235: 442-447
47. Ford J, Osborn C, Barton T and Bleehen NM (1998) A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 34: 1807-1811
48. Friedman HS, Petros WP, Friedman AH, et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525
49. Fulling K and Garcia D (1985) Anaplastic astrocytoma of the adult cerebrum; prognostic value of histologic features. Cancer 55: 928-931
50. Galanis E, Buckner JC, Schomberg PJ, et al (1997) Effective chemotherapy for advanced CNS embryonal tumors in adults. J Clin Oncol 15: 2939-2944
51. Galanis E, Buckner JC, Burch PA, et al (1998) Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group Results. J Clin Oncol (in press)
52. Germain RN and Margulies DH (1993) The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11: 403-450
53. Giannone L and Wolff S (1987) Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 71: 759-761
54. Gilbert MR, Lunsford LD, Kondziolka D, et al (1993) A phase II trial of continuous infusion chemotherapy, external beam radiotherapy and local boots radiotherapy for malignant gliomas. Proc Am Soc Clin Oncol 12: 176
55. Glass J, Hochberg FH, Gruber ML, et al (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741
56. Grant R, Slattery J, Gregor A, et al (1994) Recording neurological impairment in clinical trials of glioma. J Neuro-Oncol 19: 37-49
57. Green SB, Byar DP, Walker MD, et al (1983) Comparisons of carmustine procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121
58. Grossman SA, Wharam M, Sheidler V, et al (1997) Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15: 2596-2603
59. Grossman SA, Hochberg F, Fisher J, et al (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 432: 118-126
60. Gutin PH, Wilson CB and Kumar AR (1975) Phase II study of procarbazine, CCNU and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35: 1398-1404
61. Hoogstraten B, Gottlieb JA and Caoili E (1973) CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer: phase II study. Cancer 32: 38-43
62. Jeremic B, Grujmicic D, Jevremovic S, et al (1992) Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 10: 1074-1079
63. Karp DD, Silberman SL, Csudae R, et al (1999) Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 18: 388a
64. Kaye A and Laws E (ed) (1995) Brain Tumors: An Encyclopedic Approach. Churchill Livingstone: New York
65. Kessinger A, Lemon HM and Foley JF (1979) VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63: 511-512
66. Kohl NE, Mosser SD, deSolms J, et al (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934
67. Krishna Narla R, Liu X-P, Klis D and Uckun FM (1998) Inhibition of human glioblastoma cell adhesion and invasion by 4-(4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WH1-P131) and 4-(3′-Bromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WH1-P154). Clin Cancer Res 4: 2463-2471
68. Kyritsis AP, Yung WKA, Bruner J, Gleason MJ and Levin VA (1993) The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32: 365
69. Lampert K, Machein U, Machein MR, Conca W, Peter HH and Volk B (1998) Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 153: 429-437
70. Lesser GJ and Grossman S (1994) The chemotherapy of high-grade astrocytomas. Semin Oncol 21: 220-235
71. Levin VA, Edwards MS, Wright DC, et al (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237-241
72. Levin VA, Silver P, Hannigan J, et al (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324
73. Levin VA (2000) Phase II glioma trails with temozolomide combinations and other new agents. Cancer Invest 18: 95-96
74. Li V, Folkerth R, Watanabe H, Yu C, Rupnick M, Barnes P, Scott R, Black P, et al (1994) Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 344: 82-86
75. Luse S (1960) Electron microscopic studies of brain tumors. Neurology 10: 881-905
76. Macdonald DR, Caspar LE and Cairncross JG (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27: 573-574
77. Mak M, Fung L, Strasser JF, et al (1995) Distribution of drugs following controlled delivery to the brain interstitium. J Neuro-Oncol 26: 91-102
78. Markert JM, Medlock M, Gillespie GY, et al (1999) Preliminary report on the use of a genetically-engineered HSV-1 in the treatment of malignant glioma in humans. Neuro-Oncol 1: S106
79. Mineta T, Rabkin SD, Yazaki T, et al (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943
80. Mortimer JE, Crowley J, Eyre H, et al (1992) A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. 69: 1220-1223
81. Nelson DF, Diener-West M, Weinstein AS, et al (1986) A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 12: 1793
82. Nelson DF, Diener-West M, Horton J, et al (1988) Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group. NCI Monogr 6: 279-284
83. Newlands ES, Blackledge GRP, Slack JA, et al (1992) Phase I trial of temozolomide (CCRG 81045: M & B 3983: NSC 262856). Br J Cancer 65: 287-291
84. Newlands ES, O'Reilly SM and Glaser MG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236-2241
85. Newlands ES, Stevens MFG, Wedge SR, et al (1997a) Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat 23: 35-61
86. Newlands ES, Wedge SR, Porteous JK, et al (1997b) Temozolomide: drug scheduling in vivo and in combination with radiation. Proc Am Soc Clin Oncol 16: 393
87. O'Reilly MS (1997) Angiostatin. An endogenous inhibitor of angiogenesis and of tumor growth. In: Regulation of Angiogenesis, Goldberg ID and Rosen EM (eds). Birkhauser Verlag: Basel, Switzerland
88. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
89. Oldfield EH, Ram Z, Culver KW, et al (1993) Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39-69
90. Osaba D, Aaronson N, Sneeuw K, et al (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer specific questionnaires. Qual Life Res 5: 139-150
91. Petersdorf SH and Berger MS (1996) Concepts in neurosurgery: the molecular basis of neurosurgical disease. In: Molecular Basis of Chemotherapy for Brain Tumors, Raffel C and Harsh GR (eds) pp. 198-210. Williams and Wilkins: Baltimore
92. Phillips G, Wolff S, Fay J, et al (1986) Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol 4: 639-645
93. Plate K, Breier G, Weich H and Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529
94. Prados M, Scott C, Sandler H, et al (1997) Phase III randomized study of radiotherapy with or without PCV for the treatment of anaplastic astrocytoma: RTOG 9404 interim report. Proc ASTRO 138
95. Prados M, Yung A, Chang S, et al (1999) A phase 2 trial of Temodal® (temozolomide) in patients with anaplastic astrocytoma at first relapse. Proc Am Soc Clin Oncol 18: 139a
96. Rodriguez LA, Prados M and Silver P (1989) Revaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours. Cancer 64: 2420-2423
97. Russell D and Rubinstein L (1989) Pathology of Tumors of the Nervous System. Williams & Wilkins: Baltimore
98. Safgren SL, Reid JM, Buckner JC, Rajkumar SV, Rios R and Ames MM (1998) Pharmacokinetics of dacarbazine and its active metabolites MTIC and HMMTIC in patients with recurrent glioma. Proc Am Assoc Cancer Res 39: 327
99. Sanson M, Ameri A, Monjour A, et al (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin, and etoposide: a phase II study. Eur J Cancer 32A: 2229-2235
100. Sebag-Montefiore DJ, Douek E, Kingston JE, et al (1992) Intracranial germ cell tumours: I. Experience with platinum-based chemotherapy and implications for curative chemoradiotherapy. Clin Oncol 4: 345-350
101. Shapiro WR, Green SB, Burger PC, et al (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group trial 8001. J Neurosurg 71: 1
102. Shapiro WR, Green SB, Burger PC, et al (1992) A randomized comparison of intraarterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant gliomas. J Neurosurg 76: 772
103. Siu LL, Hidalgo M, Nemunaitis J, et al (1999) Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774: a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 18: 388a
104. Spence AM, Berger MS, Livingston RB, et al (1992) Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neuro-Oncol 12: 187-191
105. Takamiya Y, Brem H, Ojeifo J, Mineta T and Martuza RL (1994) AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurg 34: 869-875
106. Tirelli U, D'Incalci M and Canetta M (1984) Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 2: 432-437
107. Walker MD and Hurwitz BS (1970) BCNU 1,3-bis (2-chloroethyl)-1-nitrosourea, (NSC-409962) in the treatment of malignant brain tumor. A preliminary report. Cancer Chemother Rep 54: 263-271
108. Walker MD, Alexander E, Hunt WE, et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 49: 333
109. Walker MD, Green SB, Byar DP, et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323
110. Weber F, Floeth F, Rommel F (1999) Topic treatment of malignant glioma by intratumoral administration of IL-4-toxin. Neuro-Oncol 1: S105
111. Wilson CB, Bodrey EB and Enot KJ (1970) 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54: 273-281
112. Witters L, Kumar R, Mandal M, et al (1997) Antisense oligonucleotides to the epidermal growth factor receptor. Proc Am Assoc Cancer Res 38: 315
113. Yoneda T, Lyall RM, Alsina MM, et al (1991) The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro in the nude mice. Cancer Res 51: 4430
114. Yoshida S, Tanaka R, Takai N and Ono K (1990) Adoptive immunotherapy with LAK cells and interleukin-2 in the treatment of recurrent malignant gliomas. Curr Ther Res 47: 654
115. Yung WK, Harris MI and Bruner JM (1989) Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neuro-Oncol 7: 237-240
116. Yung WK, Mechtler L and Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9: 860-864
117. Yung A, Levén VA, Albright R, et al (1999) Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol 18: 139a